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ABSTRACT 
Background: Vascular calcification is an independent prognostic marker of morbidity 
and mortality in patients with chronic kidney disease on dialysis. However, since the 
previous studies included predominantly hemodialysis patients, limited information is 
available regarding the peritoneal dialysis population. Therefore, the aim of our study 
was to retrospectively evaluate an incident peritoneal dialysis population in order to 
identify factors associated with the prevalence and progression of vascular 
calcifications. Subjects and Methods: Incident peritoneal dialysis patients from 1 
January 2009 to 31 December 2011 were included in the study. Vascular calcifications 
were assessed using the simplified score of Adragão based on plain radiographs of 
pelvis and hands. Patients with and without vascular calcifications were compared for 
demographic, clinical and biochemical variables. After 12 months, the patients were 
divided according to the presence or absence of vascular calcification progression and 
compared for the aforementioned variables. Results:  Ninety-nine patients were 
included in the study. The population evaluated had a median age of 45 years and 64% 
were males. Patients with vascular calcifications at baseline (28%) were significantly 
older (p=0.002), had a higher prevalence of diabetes (p<0.001) and vascular disease 
(p=0.001), as well as higher glucose (p<0.001) and B-type natriuretic peptide (p=0.012) 
plasmatic levels. After 12 months, progression of vascular calcification was observed in 
15 of the 75 patients reevaluated. Patients with vascular calcification progression 
presented higher phosphorus plasmatic levels (p=0.011) and calcium-phosphorus 
product (p=0.015), in comparison with their baseline registers. Conclusions: In our 
population of peritoneal dialysis patients, vascular calcification at dialysis initiation was 
mainly associated with classic cardiovascular markers, such as older age, diabetes and 
elevated B-type natriuretic peptide plasmatic levels, whereas progression of vascular 
calcification were significantly associated with the calcium-phosphorus metabolism 
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parameters, reinforcing the importance of an adequate mineral and bone disorder 
control in the long term management of these patients. 
Key-words: Calcium-phosphorus metabolism; cardiovascular disease; 
peritoneal dialysis; vascular calcification. 
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RESUMO 
Introdução: A calcificação vascular é um fator de prognóstico independente de 
morbilidade e mortalidade nos doentes com doença renal crónica em diálise. Os 
estudos realizados previamente incidiram predominantemente em doentes em 
hemodiálise, pelo que a informação disponível relativamente à população em diálise 
peritoneal é limitada. Objetivos: Avaliar retrospetivamente os fatores associados à 
presença e progressão das calcificações vasculares numa população incidente em 
diálise peritoneal. Material e Métodos: Foram incluídos no estudo os doentes 
incidentes em diálise peritoneal de janeiro de 2009 a dezembro de 2011. As 
calcificações vasculares foram avaliadas através do score simplificado de Adragão, 
recorrendo a radiografias simples da pelve e das mãos. Os doentes com e sem 
calcificações vasculares foram comparados relativamente a variáveis demográficas, 
clínicas e bioquímicas. Após 12 meses, os doentes foram divididos consoante a 
presença ou não de progressão da calcificação e comparados relativamente às 
variáveis previamente mencionadas. Resultados: Foram incluídos no estudo 99 
doentes. A população avaliada tinha uma idade média de 45 anos e 62% eram do 
sexo masculino. Os doentes com calcificações vasculares (28%) eram 
significativamente mais velhos (p=0.002), apresentavam maior prevalência de diabetes 
(p<0.001) e doença vascular (p=0.001), bem como níveis plasmáticos mais elevados 
de glicose (p<0.001) e peptídeo natriurético tipo-B (p=0.012). Após 12 meses, 
verificou-se progressão da calcificação em 15 dos 75 doentes reavaliados, que 
apresentavam, comparativamente aos seus registos iniciais, valores mais elevados de 
fósforo (p=0.011) e produto fosfo-cálcio (p=0.015). Conclusões: Na população de 
doentes em diálise peritoneal avaliada, a prevalência de calcificação vascular 
associou-se principalmente a marcadores de risco cardiovascular clássicos, como 
idade avançada, diabetes e níveis plasmáticos elevados de peptídeo natrurético tipo-
B, enquanto que a progressão da calcificação vascular se correlacionou 
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significativamente com parâmetros do metabolismo fosfo-cálcio, reforçando a 
importância de um controlo adequado do metabolismo mineral ósseo na abordagem 
cardiovascular a longo prazo destes doentes. 
Palavras-chave: Calcificação vascular; diálise peritoneal; doença 
cardiovascular; metabolismo fosfo-cálcio.  
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ABBREVIATIONS  
ACEi Angiotensin-converting enzyme inhibitors 
APD Automated peritoneal dialysis 
ARB Angiotensin receptor blockers 
BMI Body mass index 
BNP B-type natriuretic peptide 
Ca x P Calcium-phosphorus product 
CAPD Continuous ambulatory peritoneal dialysis 
CaRB Calcium receptor blocker 
CBPBs Calcium-based phosphate binders 
CKD Chronic kidney disease 
CV Cardiovascular 
CVD Cardiovascular disease 
D/P Cr Dialysate-to-plasma creatinine ratio 
DBP Diastolic blood pressure 
ESRD End-stage renal disease 
FGF-23 Fibroblast growth factor-23 
HbA1c Glycated hemoglobin 
HD Hemodialysis 
HDL High-density lipoprotein cholesterol 
HR Heart rate 
iPTH Intact parathyroid hormone 
Kt/V Total weekly urea clearance 
LDL Low-density lipoprotein cholesterol 
MGP Matrix Gla protein 
PD Peritoneal dialysis 
RRT Renal replacement therapy 
SBP Systolic blood pressure 
SHPT Secondary hyperparathyroidism 
VC Vascular calcification 
VDRA Vitamin D receptor activator 
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INTRODUCTION 
 
Chronic kidney disease (CKD) is a global public health issue, with an estimated 
prevalence of 8 to 16% worldwide (1). Consequently, the number of patients with end-
stage renal disease (ESRD) requiring renal replacement therapy (RRT) is increasing 
worldwide. Peritoneal dialysis (PD), as a form of RRT, represents approximately 15% 
of the global population on dialysis (2). 
Cardiovascular disease (CVD) is the leading cause of death in patients with 
ESRD on chronic dialysis, including those on PD therapy (3, 4). Indeed, the risk of 
cardiovascular (CV) mortality in patients on dialysis is almost nine-fold higher than in 
the general population (3). This extremely high CV mortality cannot be fully explained 
by the traditional CV risk factors frequently found in the general population, such as 
dyslipidemia, diabetes, hypertension and smoking (5, 6). In fact, patients with CKD 
have their CV risk increased by a combination of both traditional and uremia-related 
risk factors (3, 6).  
Vascular calcification (VC) is now recognized as a significant link between CVD 
and CKD (7). Although VC is frequently found in the elderly, it is accelerated in CKD 
(8), being highly prevalent in ESRD patients, including those receiving PD therapy (4, 
9). In accordance to this, the prevalence of VC is higher in patients with CKD than in 
the general population, and increases with advancing stages of CKD, from 40% in 
patients with stage 3 CKD to 80–90% in patients with stage 5 CKD on dialysis (10). 
These calcifications, which occur simultaneously in the intimal and medial arterial layer, 
are independent predictors of morbidity and mortality in ESRD patients (11-14). Intimal 
calcifications, common events in general population, are associated with 
atherosclerosis whereas medial calcifications, which are markedly increased in ESRD 
patients, are associated with vascular stiffness (15). The hemodynamic consequences 
of medial calcifications include loss of arterial elasticity, an increase in pulse wave 
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velocity, the development of left ventricular hypertrophy, a decrease in coronary artery 
perfusion and myocardial ischemia (16, 17).  
Formerly, VC was seen as a passive phenomenon of calcium–phosphorus 
crystals precipitation from oversaturated plasma. Currently, however, it is recognized 
as an active process that involves vascular smooth muscle cells transformation into 
osteoblast-like cells (8).  In fact, the pathogenesis of VC in CKD is complex, involving 
numerous factors. Some of these factors are highly prevalent in the general population, 
such as older age, hypertension, diabetes and dyslipidemia, whereas others are 
intimately related to CKD, including the abnormalities that occur in mineral metabolism 
(18, 19). The relative impact of each risk factor in VC incidence and progression during 
the course of CKD is still a matter of investigation, but the development of 
abnormalities in mineral metabolism probably plays a central role in VC establishment 
(16, 17, 19). Disturbances in mineral and bone metabolism are common in CKD given 
the disruption of systemic calcium and phosphorus homeostasis, with limited excretion 
of phosphorus and diminished hydroxylation of 25-hydroxyvitamin D to calcitriol (1,25-
dihydroxyvitamin D) (17). As vitamin D deficiency and phosphorus retention progresses 
in CKD, the parathyroid glands become maximally stimulated, which causes secondary 
hyperparathyroidism (SHPT) (17). Many studies reported an association between 
serum calcium, phosphorus and calcium–phosphorus product and VC (7, 11, 20). 
Other factors related to mineral metabolism had also been associated with VC, such as 
vitamin D, fibroblast growth factor-23 (FGF-23), fetuin-A, matrix Gla protein (MGP) and 
osteoprotegerin (8, 21, 22). The role of vitamin D in the development of VC is probably 
complex, as reflected by the divalent results observed in clinical trials performed to 
evaluate the impact of the oral supplementation of this vitamin. Indeed, some authors 
describe an increased VC and mortality with the administration of high doses of Vitamin 
D (21, 23), while others suggest that lower doses may protect against VC (24).  
A number of techniques are currently available to evaluate VC, including plain 
X-ray, ultrasonography and computed tomography (10). Although the ideal screening 
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test remains controversial, plain X-ray is a widely available, simple and inexpensive 
tool that can be used to detect and monitor VC. Additionally, it can also be useful to 
differentiate medial calcification from intima calcification (11): it is suggested that 
uniform linear calcifications (angiogram-like) are representative of medial calcification 
whereas irregular patchy calcifications are associated with intimal atherosclerosis (11).  
The simplified VC score proposed by Adragão et al. is a method based on plain 
radiographic films of pelvis and hands, which allows the assessment of VC and 
accurately predicts CV risk and mortality (25, 26). 
Current therapeutic strategies for VC in ESRD population are mainly focused on 
the management of mineral bone disease associated with CKD, including the control of 
calcium and phosphorus plasmatic levels, as well as the treatment of the SHPT (4). 
The control of calcium and phosphorus levels is frequently achieved by the use of 
phosphate binders (16). The phosphate binders commonly used are sevelamer, a non-
calcium containing phosphate binder, and calcium-based phosphate binders (CBPBs), 
including calcium carbonate and calcium acetate (16). Current data comparing 
sevelamer and CBPB is inconsistent (27, 28), and the effect of the phosphate binder 
type on VC in PD population remains unclear. Concerning SHPT therapy, the use of 
vitamin D receptor activator (VDRA) has been the standard treatment (16). However, 
they elevate calcium and phosphorus levels by increasing their intestinal absorption, as 
well as their mobilization from the bone (29), which can promote VC. In order to 
suppress the SHPT without increasing calcium and phosphrus new treatment 
modalities were developed, including selective VDRA and calcimimetics agents. 
Cinacalcet hydrochloride is a calcimimetic agent that emerges as a novel therapeutic 
agent for the treatment of SHPT in patients with CKD, and is efficient in both 
hemodialysis (HD) and PD patients, reducing calcium, phosphorus, parathyroid 
hormone (PTH) and FGF-23 levels (30-32). Additionally, the use of cinacalcet was 
associated with slower progression of VC in HD patients (33).  
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 From what was previously exposed, we can conclude that VC is an important 
cardiovascular prognostic marker for patients with CKD on dialysis, which 
pathophysiology, assessment and management is still a matter of debate, particularly 
in patients on PD. Therefore, the aim of our study was to retrospectively evaluate VC in 
an incident PD population in order to identify factors associated with both VC 
prevalence and progression. 
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SUBJECTS AND METHODS 
 
General Design 
A retrospective, observational study was performed to investigate the impact of 
selected demographic, clinical, pharmacologic and PD-related factors on the 
prevalence and progression of VC in an incident PD population. 
Subjects  
The medical records of 139 incident patients at the PD Unit of Hospital de S. 
João from 1 January 2009 to 31 December 2011 were reviewed. All the patients 
without plain radiographs of pelvis and hands within the first 3 months of PD therapy 
were excluded (40 patients); the remaining 99 patients were included in the baseline 
characterization. The study population was subsequently divided in two groups 
according to the presence of VC at baseline and compared for demographic, clinical 
and biochemical variables. After 12 months, the 75 patients who remained on PD 
therapy were divided in two groups according to the progression of VC and compared 
for the aforementioned variables. The VC progression was defined as a VC score after 
12 months higher than the VC score at baseline. The clinical characteristics of the 15 
patients who presented VC progression were also compared, at the beginning of the 
study period and after 1 year of PD therapy. 
Data Collection  
Data collection was registry-based. Clinical information, including CV risk 
factors, relevant medical antecedents and usual medications were obtained from the 
last registry before initiation of PD. The antecedents recorded included history of 
diabetes, hypertension, vascular disease (defined as coronary, cerebrovascular or 
peripheral vascular disease) and previous RRT (HD or renal transplantation). 
Pharmacologic profile included angiotensin-converting enzyme inhibitors (ACEi), 
angiotensin receptor blockers (ARB), β-blockers, calcium receptor blockers (CaRB), 
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diuretics, antiplatelet agents, warfarin, statins, erythropoiesis-stimulating agents, 
calcium carbonate, sevelamer, VDRA and cinacalcet.  
Data on anthropometric parameters, systolic blood pressure (SBP), diastolic 
blood pressure (DBP), heart rate (HR), PD-related factors and general biochemical 
profile were collected from the first registry following PD therapy initiation and after 12 
months. Anthropometric parameters included weight and body mass index (BMI). The 
PD-related factors recorded were PD modality (automated peritoneal dialysis - APD or 
continuous ambulatory peritoneal dialysis – CAPD), total renal clearance, diuresis, total 
weekly urea clearance (Kt/V), total creatinine clearance and dialysate-to-plasma 
creatinine ratio (D/P Cr), obtained after a 4-hour peritoneal equilibration test performed 
with a hypertonic PD solution. Analytic profile included hemoglobin, albumin, alkaline 
phosphatase, total cholesterol, low-density lipoprotein cholesterol (LDL), high-density 
lipoprotein cholesterol (HDL), triglycerides, glucose, glycated hemoglobin (HbA1c), 
calcium, phosphorus, calcium-phosphorus product (Ca x P), C-reactive protein, pH, 
bicarbonate, intact parathyroid hormone (iPTH) and B-type natriuretic peptide (BNP). 
Assessment of VC  
VC was evaluated at baseline and after 12 months on PD therapy by plain 
radiographs of pelvis and hands, using the simplified score developed by Adragão et al 
(25). The pelvic radiographs were divided into four sections by two imaginary lines: a 
horizontal line over the upper limit of both femoral heads and a median vertical line 
over the vertebral column. The radiographs of the hands were divided, for each hand, 
by a horizontal line over the upper limit of the metacarpal bones. The presence of linear 
vascular calcifications in each section was counted as 1 and its absence as 0. The final 
score was the sum of all the sections, ranging from 0 to 8.  
Statistical Analysis  
Statistical analysis was performed using IBM® SPSS® Statistics Version 22, for 
Windows®. Continuous variables were expressed as mean ± standard deviation or as 
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median (range). Categorical variables were expressed as frequency and percentage. 
Comparisons between continuous variables were performed using the t-test or the 
Mann Whitney U test for independent samples, and t-test or Wilcoxon test for paired 
samples. Categorical variables were compared using the chi-square test or Fisher’s 
exact test. P values < 0.05 were considered statistically significant. 
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RESULTS 
 
Baseline characterization of the patients studied  
Baseline characterization of the 99 patients studied is presented in Table I. The 
median age of this incident PD population was 45 years (range from 16 to 89 years), 
with 61 (62%) males and 38 (38%) females. CAPD was the predominant modality in 
our population and was used in 93% of the patients. All patients used standard 
bicarbonate based PD solutions (Physioneal, Baxter, USA) with 1.25 mmol/L of 
calcium. Glomerulonephritis was the most common identified cause of CKD (22%), 
followed by diabetes (17%) and hypertension (10%).  
In this population, the prevalence of diabetes was 29% (83% type 2 and 17% 
type 1), 85% were hypertensive and 23% had documented vascular disease (48% had 
history of cardiovascular disease, 42% of cerebrovascular disease and 10% of 
peripheral vascular disease).  
Regarding the pharmacologic profile, 90% of the patients were treated with at 
least one class of anti-hypertensive drugs and 76% had their anemia treated with an 
erythropoiesis-stimulating agent. Among the drugs that target mineral metabolism 
disturbances, calcium carbonate was the predominant chelating agent prescribed (36% 
for calcium carbonate and 24% of sevelamer use), and VDRA were more often used 
for the treatment of hyperparathyroidism than cinacalcet (31% vs. 9%). The VDRAs 
used were calcitriol (20% of the patients) and alphacalcidol (11% of cases). The 
dosage of VDRA prescribed ranged from 1.5 to 3.5 mcg per week, with a median of 1.5 
mcg per week. 
The prevalence of VC at baseline was 28%, with a median calcification score in 
these patients of 4 (range from 1 to 8).  
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Characterization of the population of patients with VC at baseline 
The characterization of the population of patients with VC at baseline is 
displayed in Table II. The patients with VC at baseline, when compared with those 
without VC, were older (median 59 years vs. 42 years, p=0.002) and had a higher 
prevalence of both diabetes (75% vs. 11%, p<0.001) and vascular disease (50% vs. 
17%, p=0.001). Patients with VC at baseline presented a higher BMI (28 ± 4 vs. 26 ± 4 
kg/m2, p=0.014) and a lower DBP (71 ± 16 vs. 81 ± 14 mmHg, p=0.004) than those 
without VC at baseline. No significant difference was observed in SBP or HR values 
between the two groups. Furthermore, no differences were found in the other 
demographic or clinical variables evaluated.  
The treatment with β-blocker agents was more frequent in patients with VC than 
in those without VC (68 vs. 35%, p=0.003). The proportion of patients taking 
antiplatelet agents was also significantly higher in the group presenting VC at baseline 
(one antiplatelet agent: 32 vs. 14%, p=0.043; two antiplatelet agents: 18% vs. 4%, 
p=0.039). No differences were observed in the use of other drugs, including warfarin 
and drugs directed to the calcium-phosphorus metabolism, such as calcium carbonate, 
sevelamer, VDRA and cinacalcet. 
Regarding the biochemical profile, plasmatic BNP (median 199 vs. 99 pg/mL, 
p=0.012), glucose plasmatic levels (median 138 vs. 87 mg/dL, p<0.001) and HbA1c 
(median 6.7 vs. 5.4%, p<0,001) were significantly higher in patients with VC at 
baseline. On the contrary, albumin plasmatic levels were significantly lower in this 
group (35.0 ± 5.3 vs. 38.6 ± 4.4 g/L, p=0.001). No significant differences were found in 
other biochemical parameters, including those related to calcium-phosphorus 
metabolism, such as calcium, phosphorus, calcium-phosphorus product and iPTH. 
Patients with VC at baseline presented a lower peritoneal transport profile (D/P 
Cr: 0.7 ± 0.1 vs. 0.8 ± 0.1, p=0.037), and a significantly higher total creatinine 
clearance (188 ± 87 vs. 127 ± 59 L/week, p=0.004). In the group of patients with VC, a 
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higher renal clearance (median 8.6 vs. 6.1 mL/min, p=0.018) was also observed. No 
differences were documented in the remaining PD-related variables. 
Characterization of the population of patients with VC progression 
The characterization of the patients reevaluated after one year on PD therapy is 
presented in Table III. Twenty-four patients were not evaluated for VC progression: 3 
patients died, 2 were transferred to HD, 8 were submitted to renal transplantation and 
11 had no radiographs of pelvis and hands to assess VC progression. Therefore, 75 
patients were included in the second evaluation.  
Vascular calcification progression was observed in 15 patients (20%). Of these, 
9 (60%) already had VC at baseline, while 6 (40%) displayed de novo VC (p=0.014). 
Comparatively to those without VC progression, patients that progressed were 
significantly older (median 63 vs. 46 years, p=0.016) and had a higher prevalence of 
diabetes (60 vs. 27%, p=0.014) and vascular disease (60 vs. 23%, p=0.011). Patients 
with VC progression presented significantly higher SBP (149 ± 30 vs. 132 ± 25 mmHg, 
p= 0.031) when compared to the non-progressing group. No significant differences 
were observed in DPB or HR values between the two groups. Additionally, no 
differences were found in the other demographic or clinical variables. 
Pharmacologically, the proportion of patients taking ARB (60 vs. 23%, p=0.011) 
and β-blockers (80 vs. 48%, p=0.028) was higher in the group with VC progression. No 
differences in the use of other drugs were documented, including warfarin and drugs 
directed to the calcium-phosphorus metabolism, such as calcium carbonate, 
sevelamer, VDRA and cinacalcet. 
Analytically, patients with VC progression had higher glucose (median 104 vs. 
99 mg/dL, p=0.023) and BNP plasmatic levels (median 321 vs. 67 pg/mL, p=0.001) 
when compared to the non-progressing group. No differences were found in the other 
biochemical parameters, including plasmatic levels of calcium, phosphorus, calcium-
phosphorus product and PTH. 
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Patients with VC progression presented a faster peritoneal transport profile (D/P 
Cr 0.8 ± 0.04 vs. 0.7 ± 0.1 mg/dL, p=0.006) when compared to the patients without VC 
progression. On the contrary, total creatinine clearance and renal clearance were 
similar between the two groups. 
The analytic characterization of the subpopulation of PD patients that presented 
VC progression after 1 year on PD therapy is shown in Table IV. The biochemical 
profile of the 15 patients who had VC progression after 1 year, in comparison to that 
registered at the beginning of PD therapy, presented significantly higher phosphorus 
plasmatic levels (median 5.0 vs. 3.8 mg/dL, p=0.011) and higher calcium-phosphorus 
product (45 vs. 33 mg2/dL2, p=0.015). No differences were found in the other analytical 
parameters. 
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DISCUSSION 
 
In the population of PD patients studied vascular calcification evaluated by a 
simplified score was frequent, being present in more than one quarter of the patients at 
the beginning of RRT and in 20% of the sample after one year of PD therapy. The 
presence of VC at baseline was mainly associated with traditional cardiovascular risk 
markers, such as older age, diabetes and elevated BNP plasmatic levels, whereas the 
progression of VC correlated also with some of the parameters of the calcium-
phosphorus metabolism, namely phosphorus plasmatic levels and calcium-phosphorus 
product. 
The prevalence of VC in our incident PD population was 28%, which was lower 
than that reported in the majority of the previous studies (13, 14, 19). This difference 
may be partly explained by the intrinsic characteristics of the population studied (age, 
CKD etiology or diabetes prevalence) or to the screening technique used to determine 
the presence of VC. Despite this, VC seems to be a frequent finding in these patients 
at the beginning of RRT, reflecting the importance of timely referral to pre-dialysis care 
in the cardiovascular risk modulation of advanced CKD patients. 
In the present study, age correlated positively with both the prevalence and 
progression of VC, which is in line with previous evidence in this area (12, 13). 
Additionally, in accordance with previous studies (13, 34), both diabetes history and 
poorly controlled glucose levels were more frequent in patients with VC at baseline, as 
well as in those experiencing VC progression after one year on PD therapy. Despite 
the fact that glucose was previously implicated in the calcification process in bovine 
vascular smooth muscle cells (35), the association between diabetes and VC may also 
be attributed to an unfavorable lipid profile deriving from an insulin resistance state and 
visceral fat accumulation (13). However, in the present study, no difference was found 
in the lipid profile between patients with and without VC, neither the proportion of 
patients taking statins was significantly different between groups. One possible 
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explanation for these results is the fact that we have assessed medial calcification, and 
the lipid profile appears to be predominantly associated with atherosclerosis and intimal 
calcification. Moreover, fasting plasma glucose seems to be a better independent 
determinant of the progression of VC than the other metabolic syndrome risk factors 
(36).  
In our PD population BNP plasmatic levels were significantly higher in patients 
with VC at baseline, as well as in those who experienced VC progression over 1 year 
on PD therapy.  Fluid overload, frequent in ESRD patients, stimulates the secretion of 
BNP by the myocardium. The role of BNP on the VC process in PD population remains 
unclear, but it is known that serum BNP levels are more than 10-fold higher in patients 
on PD than in the general population, and are associated with CV mortality (37). 
Additionally, BNP circulating levels in these patients may also be related to the 
presence of heart failure or the degree of residual renal function, as previously 
suggested (37). Despite the possible interference of all these factors, the association 
between VC and BNP circulating levels that we have observed probably reflects the 
overall cardiovascular risk profile of this dialysis population and may assist in the early 
detection of a subgroup of patients more disposed to VC development. 
In our patients, the use of β-blockers was positively correlated to the presence 
of VC at baseline and to the progression of VC. In fact, β-blockers may promote VC 
through sympathetic activity modulation, influencing the trophic effects of this system 
on the peripheral vasculature (38). However, it should be noted that β-blockers are 
frequently prescribed to patients with higher cardiovascular risk, which might constitute 
by itself a confounding factor for the association of these agents to VC. Even so, we 
can speculate if the different cardio-modulating pharmacological agents frequently 
used in PD patients may have a distinct impact in the risk of VC progression and, for 
that reason, be preferred over the other therapeutic possibilities in patients more prone 
to VC development.  
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The present study did not found any difference regarding the treatment with 
warfarin in PD patients, whereas treatment with antiplatelet agents was positively 
associated with VC. It is known that warfarin impairs the synthesis and function of the 
MGP, a vitamin K–dependent protein that is a potent inhibitor of tissue calcification 
(39). The absence of a statistically significant association between warfarin therapy and 
VC may be explained by the limited proportion of patients taking warfarin in our 
population. The role of antiplatelet agents for cardiovascular disease management in 
ESRD remains unclear (40), but they are frequently prescribed to patients with an 
elevated CV risk profile and with a higher prevalence of disrupted vascular function. 
In this study, we have not identified a significant association between C-reactive 
protein plasmatic levels and the progression of VC. Inflammation is a recognized 
stimulus for vascular calcification and C-reactive protein has been associated with 
progression of VC in HD patients (41). Our findings are in accordance with previous 
observations (13) and may be explained by the fact that PD patients, for reasons 
mainly related to the intrinsic characteristics of the dialysis modality, may be less 
exposed to immunogenic materials and, as a consequence, less inflamed. A study 
directed to evaluate the relation between different inflammatory markers and VC in 
patients treated with HD or PD would be, naturally, very informative.   
In our population no difference was found in the calcium and phosphorus 
metabolism between patients with and without VC at baseline. However, it is 
noteworthy that a higher phosphorus plasmatic levels and calcium-phosphorus product 
was observed after 1 year of PD therapy in the group of patients who presented VC 
progression. Despite the relative importance attributed by different authors to the 
factors previously mentioned, the calcium-phosphorus metabolism has been profoundly 
implicated in VC process. In fact, VC was previously associated with the degree of 
calcium and phosphorus control, the suppression of PTH, and the use of CBPBs (18). 
In this study, no difference was found regarding the type of P-binder used. Although 
some studies reported that treatment with sevelamer had a significant role in the 
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attenuation of the VC progression when compared to CBPBs (27), others did not found 
significant differences between these two forms of therapy (28), particularly during the 
first year on dialysis (42). An explanation proposed for the protective effect of 
sevelamer was the influence in lipid profile, decreasing LDL levels (16). In vitro studies 
have shown that LDL promotes vascular smooth muscle cells calcification, whereas 
HDL inhibits it (43). Thus, the improvement in lipid profile might play a role in the lower 
degree of VC observed after sevelamer therapy. This theory was corroborated in a 
study in HD patients, who reported similar VC progression rates between a group 
treated with calcium acetate plus intensive lowering of LDL levels with atorvastatin and 
other treated with sevelamer alone (28). Our population presented a controlled lipid 
profile and the LDL plasmatic levels were below the value associated with increased 
CV risk, probably explaining the absence of correlation between sevelamer therapy 
and VC prevalence and progression.  
In the present study no association was found between VDRA use and VC. It is 
known that use of VDRA results in the elevation of calcium and phosphorus plasmatic 
levels by increasing their intestinal absorption, as well as by their mobilization from the 
bone (29). In our PD population mainly non-selective VDRA were used. Even though 
non-selective and selective VDRA are both effective in inducing suppression of PTH 
secretion, selective VDRA may cause less hypercalcaemia and hyperphosphataemia 
due to their cellular selectivity (44), and have been reported to grant a survival 
advantage over non-selective VDRA (45). The absence of correlation between Vitamin 
D supplementation and VC progression in our study may be explained by the 
predominant use of non-selective VDRA agents, counteracting the possible survival 
advantage of VDRA therapy in the calcification process. More trials will be required to 
clarify the role of VDRA in VC development, as well as to determine the influence of the 
different types of VDRA in VC progression in the PD population. 
Concerning the treatment with cinacalcet, an agent recently developed for 
SHPT management without increasing calcium and phosphorus, no difference was 
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found in our study between patients with and without VC at baseline and after 1 year of 
PD therapy. Previous studies have documented an association between cinacalcet 
therapy and a slower progression of VC, when compared to flexible doses of vitamin D 
alone (33). Additionally, it was reported a case of regression of VC in a patient treated 
with cinacalcet (46). In the present study, the limited use of cinacalcet in our population 
may have contributed to the absence of significant differences observed. Nevertheless, 
data regarding the impact of cinacalcet therapy in VC is still very limited and more trials 
will be necessary to confirm the role of this therapeutic agent in VC modulation.  
With respect to PD-related variables, patients with VC progression revealed a 
faster peritoneal transport profile when compared to patients without VC progression, 
whereas patients with VC at baseline presented a slower peritoneal transport than 
those without VC. Actually, several studies have linked fast peritoneal transport with 
higher mortality in PD (47), but its relation with VC is not well established. The patients 
with VC at baseline presented also a higher total renal clearance. These results 
appears to be contradictory, since VC is positively related to mortality (11-14) and the 
residual renal function is inversely correlated with mortality on PD patients (48). One 
possible explanation may rely on the fact that, as previously observed in other studies, 
the rate of decline of residual renal function may be more powerful in predicting all-
cause mortality in the PD population than baseline residual renal function (49). Other 
possible explanation may be related to a more precocious referral to RRT of patients 
with a higher CV disease burden that may also present, at baseline, a higher risk for 
VC development. 
 Finally, in concordance with previous studies, VC progression was more 
frequent in patients who presented VC at baseline (12, 13). In fact, patients without 
visible calcification often do not experience VC progression or only have minimal VC 
over the time on dialysis (42). These findings raise the possibility that some patients 
may be “protected” against VC and express a lighter form of vascular disease even in 
the presence of advanced CKD. The identification of factors possibly associated to this 
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protective profile is imperative, as it may contribute to the development of new 
therapeutic strategies oriented to limit VC development in dialysis patients. 
We recognize important limitations of this study, mainly inherent to its 
retrospective and single-center nature, which can be a source of bias. On the other 
hand, the number of patients evaluated is the main strength of our work, since previous 
studies in PD patients presented, generally, limited samples. 
In conclusion, in our population of PD patients VC was a common finding at the 
beginning of RRT and was associated with some of the classical CV risk markers, such 
as older age, diabetes and elevated BNP levels. Vascular calcification progression 
after 1 year on PD therapy was mainly observed in patients with VC at baseline and 
less frequent in patients without VC in the first assessment. Despite the known impact 
of the calcium-phosphorus metabolism on VC development, we have documented a 
positive correlation between phosphorus plasmatic levels and calcium-phosphorus 
product and VC only in the subpopulation of PD patients that presented VC 
progression after 1 year on PD therapy, reinforcing the importance of an adequate 
SHPT control in the long term management of the cardiovascular risk of these patients.  
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TABLES 
 
TABLE I 
Baseline characterization of the patients studied (n=99) 
Age (years) 45 (16-89) 
Male gender  61 (62%) 
Diabetes 29 (29%) 
Hypertension 84 (85%) 
Smoking 20 (20%) 
Vascular Disease  23 (23%) 
Cardiovascular Disease 14 (14%) 
Cerebrovascular Disease 12 (12%) 
Peripheral Vascular Disease 3 (3%) 
CKD Etiology  
Diabetes 17 (17%) 
Hypertension 10 (10%) 
Glomerulonephritis 22 (22%) 
Polycystic kidney disease 8 (8%) 
Undetermined 25 (26%) 
Other 17 (17%) 
Previous HD therapy 21 (21%) 
Previous renal transplantation  6 (6%) 
Weight (Kg)  71 ± 14 
BMI (kg/m2)  26 ± 4 
SBP (mmHg)  139 ± 23 
DBP (mmHg) 78 ± 15 
HR  76 ± 13 
Pharmacologic profile   
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ACEi 44 (44%) 
ARB 25 (25%) 
β-blocker 44 (44%) 
CaRB 53 (54%) 
Diuretic 72 (73%) 
One antiplatelet agent   19 (19%) 
Two antiplatelet agents 8 (8%) 
Warfarin 4 (4%) 
Statin 53 (54%) 
Calcium carbonate 36 (36%) 
Sevelamer 24 (24%) 
Vitamin D receptor activator  31 (31%) 
Calcitriol 20 (20%) 
Alphacalcidol 11 (11%) 
Dosage/week (mcg) 1,5 (0,5-3,5) 
Erythropoiesis-stimulating agent 75 (76%) 
Cinacalcet 9 (9%) 
Biochemical profile   
Hemoglobin (g/dL)  11,7 ± 1,5 
Albumin (g/L)  37,6 ± 4,9 
Alkaline Phosphatase (U/L)  90 (10-310) 
Total Cholesterol (mg/dL)  191 ± 50 
HDL (mg/dL)  46 (13-204) 
LDL (mg/dL)  102 ± 44 
Triglycerides (mg/dL)  143 (55-565) 
Glucose (mg/dL)  92 (57-308) 
HbA1c (%)  5,7 (3,9-11,3) 
Calcium (mg/dL)  9,2 (7,2-11,0) 
Phosphorus (mg/dL)  4,2 (1,2-12,2) 
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Ca x P (mg
2
/dL
2
)  39 (11-98) 
C-reactive protein (mg/L)  4,0 (0,2-84,8) 
pH  7,3 (7,1-7,5) 
Bicarbonate (mmol/L) 28,4 (13,9-62,5) 
iPTH (pg/mL)  316 (41-1578) 
BNP (pg/mL)  127 (11-2308) 
PD-related variables  
PD modality  
CAPD 92 (93%) 
APD  7 (7%) 
Total Renal Clearance (mL/min)  7,2 (0-38,0) 
Diuresis (mL)  1500 (0-4600) 
Kt/V  2,3 (0,8-8,4) 
Total Clearance (L/week)  144 ± 72 
D/P Cr (mg/dL)  0,75 ± 0,10 
Vascular Calcification  28 (28%) 
 
Results are expressed in: frequency (percentage); median (range); mean (standard deviation). 
 
 
 
 
 
 
 
 
. 
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TABLE II 
Characterization of the Patients Without and With VC at Baseline  
 Without VC (n=71) With VC (n=28) p Value 
Age 42 (16-89) 59 (25-80) 0,002
a
 
Gender Male  42 (59%) 19 (68%) 0,423
b
 
Diabetes  8 (11%) 21 (75%) <0,001
b
 
Hypertension  58 (82%) 26 (93%) 0,221
c
 
Smoking  15 (21%) 5 (18%) 0,698
b
 
Vascular Disease   12 (17%) 14 (50%) 0,001
b
 
CKD    
Previous HD therapy  15 (21%) 6 (21%) 0,974
b
 
Previous renal transplantation  2 (3%) 4 (14%) 0,052
c
 
Weight (kg)  69 ± 14 76 ± 11 0,021
d
 
BMI (kg/m2) 26 ± 4 28 ± 4 0,014
d
 
SBP (mmHg)  138 ± 20 141 ± 27 0,580
d
 
DPB (mmHg)  81 ± 14 71 ± 16 0,004
d
 
HR  76 ± 12 72 ± 15 0,157
d
 
Pharmacological profile     
ACEi 34 (48%) 10 (36%) 0,272
b
 
ARB 16 (22%) 9 (32%) 0,322
b
 
β-blocker 25 (35%) 19 (68%) 0,003
b
 
CaRB 34 (48%) 19 (68%) 0,073
b
 
Diuretic 49 (69%) 23 (82%) 0,149
b
 
One antiplatelet agent 10 (14%) 9 (32%) 0,043
b
 
Two antiplatelet agents 3 (4%) 5 (18%) 0,039
c
 
Warfarin 2 (3%) 2 (7%) 0,317
c
 
Statin 35 (49%) 18 (64%) 0,178
b
 
Calcium carbonate 23 (32%) 13 (46%) 0,191
b
 
Sevelamer 20 (28%) 4 (14%) 0,147
b
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Vitamin D receptor activator 25 (35%) 6 (21%) 0,183
b
 
Calcitriol 16 (64%) 4 (67%) 1,000
c
 
Alphacalcidol 9 (36%) 2 (33%)  
Dosage/week (mcg) 1,5 (0,5-3,5) 1,5 (0,75-3,0) 0,770
a
 
Erythropoiesis-stimulating agent 52 (73%) 23 (82%) 0,352
b
 
Cinacalcet 7 (10%) 2 (7%) 1,000
c
 
Biochemical profile    
Hemoglobin (g/dL)  11,6 ± 1,5 12,0 ± 1,5 0,257
d
 
Albumin (g/L)  38,6 ± 4,4 35,0 ± 5,3 0,001
d
 
Alkaline Phosphatase (U/L)  87 (10-310) 110 (42-258) 0,062
a
 
Total Cholesterol (mg/dL)  193 ± 51 185 ± 49 0,431
d
 
HDL (mg/dL)  49 (13-204) 44 (24-147) 0,192
a
 
LDL (mg/dL)  102 ± 45 103 ± 43 0,932
d
 
Triglycerides (mg/dL)  145 (55-565) 135 (69-494) 0,747
a
 
Glucose (mg/dL)  87 (57-167) 138 (67-308) <0,001
a
 
HbA1c (%)  5,4 (3,9-11,3) 6,7 (5,4-10,9) <0,001
a
 
Calcium (mg/dL)  9,2 (7,2-11,0) 9,2 (7,2-10,4) 0,731
a
 
Phosphorus (mg/dL)  4,3 (2,3-9,4) 4,1 (1,2-12,2) 0,228
a
 
Ca x P (mg
2
/dL
2
)  38,7 (21,3-84,6) 34,9 (10,5-97,6) 0,208
a
 
C-reactive protein (mg/L)  3,7 (0,2-84,8) 5,4 (0,8-38,8) 0,797
a
 
pH  7,3 (7,1-7,5) 7,3 (7,2-7,4) 0,091
a
 
Bicarbonate (mmol/L)  28,0 (13,9-62,5) 29,0 (17,0-35,2) 0,220
a
 
iPTH (pg/mL)  316 (41-1578) 298 (91-957)  0,870
a
 
BNP (pg/mL)  99 (11-2076) 199 (25-2308) 0,012
a
 
PD-related variables    
PD modality    
CAPD 65 (92%) 27 (96%) 0,669
c
 
APD 6 (8%) 1 (4%) 
Total renal clearance (mL/min)  6,1 (0-19,4) 8,6 (0-38,0) 0,018
a
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Diuresis (mL)  1500 (0-4600) 1600 (0-3000) 0,725
a
 
Kt/V  2,2 (0,8-4,9) 2,4 (1,5-8,4) 0,389
a
 
Total clearance (L/week)  127 ± 59 188 ± 87 0,004
d
 
D/P Cr (mg/dL)  0,8 ± 0,1 0,7 ± 0,1 0,037
d
 
 
Results are expressed in: frequency (percentage); median (range); mean (standard deviation).  
a 
Mann-Whitney U; 
b
 Chi-square; 
c 
Fisher’s exact test; 
d
 t-test.  
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TABLE III 
Characterization of the Patients Without and With VC Progression 
 Without VC 
progression (n=60) 
With VC progression 
(n=15) 
p Value 
Age 46 (17-90) 63 (37-76) 0,016
a
 
Gender Male  36 (60%) 10 (67%) 0,635
b
 
Diabetes  16 (27%) 9 (60%) 0,014
b
 
Hypertension  47 (78%) 15 (100%) 0,059
c
 
Smoking  10 (17%) 3 (20%) 0,412
c
 
Vascular Disease  14 (23%) 9 (60%) 0,011
c
 
CKD    
Previous HD therapy  7 (12%) 4 (27%) 0,215
c
 
Previous renal transplantation   3 (5%) 2 (13%) 0,260
c
 
Weight (kg)  71 ± 14 73 ± 13 0,593
d
 
BMI (kg/m2) 27 ± 4 27 ± 4 0,769d 
SBP (mmHg)  132 ± 25 149 ± 30 0,031
d
 
DPB (mmHg)  76 ± 14 76 ± 14 0,935
d
 
HR  76 ± 14 76 ± 15 0,875
d
 
Pharmacologic profile     
ACEi 38 (63%) 8 (53%) 0,477
b
 
ARB 14 (23%) 9 (60%) 0,011
c
 
β-blocker 29 (48%) 12 (80%) 0,028
b
 
CaRB 30 (50%) 10 (67%) 0,247
b
 
Diuretic 44 (73%) 14 (93%) 0,057
c
 
One antiplatelet agent 11 (18%) 5 (33%) 0,289
c
 
Two antiplatelet agents 5 (8%) 2 (13%) 0,622
c
 
Warfarin 3 (5%) 1 (7%) 1,000
c
 
Statin 44 (73%) 13 (87%) 0,499
c
 
Calcium carbonate 14 (23%) 7 (47%) 0,106
c
 
Sevelamer 28 (47%) 6 (40%) 0,643
b
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Vitamin D receptor activator 38 (63%) 7 (47%) 0,239
b
 
Calcitriol 9 (24%) 2 (29%) 1,000
c
 
Alphacalcidol 29 (76%) 5 (71%)  
Dosage/week (mcg) 1,0 (0,5-3,5) 1,0 (0,75-3,5) 0,691
a
 
Erythropoiesis-stimulating agent 41 (68%) 13 (86%) 0,496
c
 
Cinacalcet 21 (35%) 5 (33%) 0,903
b
 
Biochemical profile    
Hemoglobin (g/dL)  11,5 ± 1,7 10,9 ± 1,8 0,190
d
 
Albumin (g/L)  38,2 ± 3,9 36,1 ± 4,6 0,075
d
 
Alkaline Phosphatase (U/L)  107 (48-402) 105 (35-328) 0,882
a
 
Total Cholesterol (mg/dL)  180 ± 37 163 ± 37 0,107
d
 
HDL (mg/dL)  47 (28-91) 43 (29-67) 0,589
a
 
LDL (mg/dL)   103 ± 29 88 ± 35 0,097
d
 
Triglycerides (mg/dL)  136 (66-841) 128 (50-264) 0,804
a
 
Glucose (mg/dL)  89 (50-380) 104 (76-190) 0,023
a
 
HbA1c (%)  5,7 (4,6-8,9) 6,0 (5,0-11,8) 0,054
a
 
Calcium (mg/dL)  9,0 (7,2-18,8) 9,0 (7,6-10,6) 0,433
a
 
Phosphorus (mg/dL)  4,6 (3,2-7,8) 5,0 (3,2-6,3) 0,605
a
 
Ca x P (mg
2
/dL
2
)  41 (28-132) 45 (29-53) 0,676
a
 
C-reactive protein (mg/L)  2,3 (0,3-30,3) 3,9 (0,5-105,4) 0,114
a
 
pH  7,3 (7,2-7,5) 7,3 (7,2-7,4) 0,721
a
 
Bicarbonate (mmol/L)  28,9 (18,6-36,5) 28,8 (31,2-41,7) 0,545
a
 
iPTH (pg/mL)  409 (129-1441) 408 (38-1245) 0,968
a
 
BNP (pg/mL)  67 (11-1350) 321 (23-19154) 0,001
a
 
PD-related variables    
PD modality    
CAPD 53 (88%) 12 (80%) 
0,408
c
 
APD 7 (12%) 3 (20%) 
Total renal clearance (mL/min)  5,7 (0-17,84) 7,2 (0-17,5) 0,936
a
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Diuresis (mL)  1500 (0-2850) 1250 (0-2600) 0,236
a
 
Kt/V  2,0 (0,9-4,5) 2,3 (1,2-4,3) 0,438
a
 
Total clearance (L/week)  123 ± 62 130 ± 77 0,674
d
 
D/P Cr (mg/dL)  0,7 ± 0,1 0,8 ± 0,04 0,006
d
 
 
Results are expressed in: frequency (percentage); median (range); mean (standard deviation).  
 
a 
Mann-Whitney U; 
b
 Chi-square; 
c 
Fisher’s exact test; 
d
 t-test. 
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TABLE IV 
Biochemical  Profile of the Patients With VC Progression  
 Baseline (n=15) After 1 Year (n=15) p Value 
Hemoglobin (g/dL)  11,7 ± 1,6 10,9 ± 1,3 0,146
a
 
Albumin (g/L)  36,3 ± 3,8 36,1 ± 4,5 0,879
a
 
Alkaline Phosphatase (U/L)  112 (40-237) 109 (34-328) 0,551
b
 
Total Cholesterol (mg/dL)  169 ± 41 163 ± 37 0,497
a
 
HDL (mg/dL)  44 ± 12 45 ± 11 0,618
a
 
LDL (mg/dL)   95 ± 34 88 ± 35 0,453
a
 
Triglycerides (mg/dL)  124 (69-494) 128 (50-264) 0,670
b
 
Glucose (mg/dL)  98 (78-279) 104 (76-190) 0,113
b
 
HbA1C (%)  6,2 (5,4-10,9) 6,0 (5,0-11,8) 0,753
b
 
Calcium (mg/dL)  8,9 ± 0,8 8,8 ± 0,8 0,626
a
 
Phosphorus (mg/dL)  3,8 (1,2-12,2) 5,0 (3,2-6,3) 0,011
b
 
Ca x P (mg
2
/dL
2
)  33,3 (10,5-97,6) 45,0 (29,4-53,0) 0,015
b
 
C-reactive protein (mg/L)  6,3 (0,8-38,8) 3,5 (0,5-55,9) 0,114
a
 
pH  7,3 ± 0,05 7,3 ± 0,06 0,594
b
 
Bicarbonate (mmol/L)  28,9 (18,6-36,5) 28,8 (31,2-41,7) 0,281
b
 
iPTH (pg/mL)  347 (90-1321) 408 (38-1545) 0,233
b
 
BNP (pg/mL)  203 (60-2308) 321 (23-19154) 0,061
b
 
 
Results are expressed in: median (range); mean (standard deviation);  
a 
t-test for pared groups; 
b Wilcoxon. 
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